SAS Output

25-APR-2019 6:10

GI ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1613-mCRC, Adv/Met, TP vs CETIRI 1 Y 0 Screening 130 146 125 56 27 10 4 11/27/2017 292 113
            146 125 56 27 10 4      
 
    2 Y 1 Trastuzumab + Pertuzumab 130 10 9 6 2 0 0 11/27/2017    
        2 Cetuximab + Irinotecan   11 11 5 4 2 0      
            21 20 11 6 2 0      
 
    3 Y 3 Crossover: Trastuz + Pertuz 130 7 7 4 4 3 1 11/27/2017    
            7 7 4 4 3 1      
 
  S1815-Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel 1 Y 1 Gem+Cisplatin+Nab-paclitaxel 268 11 11 11 11 5 1 02/07/2019 172 71
        2 Gemcitabine + Cisplatin   6 6 6 6 3 1      
            17 17 17 17 8 2      
 
Yes A021502-Colon, Stg III, Chemo +/- Atezol, ATOMIC 1 E Total Registrations   14 12 8 4 2 0 03/23/2018 334 161
            14 12 8 4 2 0      
 
No A021501-Adeno Panc,Borderline Resect,Chemo vs ChemoRT 0 E Total Registrations   19 1 1 1 0 0 05/01/2017   1
            19 1 1 1 0 0      
 
    1 E Total Registrations   16 2 1 1 0 0 05/01/2017    
            16 2 1 1 0 0      
 
  EA2142-GI NEC, Adv G3, EP vs TMZ + CAP 1 E Total Registrations   4 0 0 0 0 0 07/14/2016 189 78
            4 0 0 0 0 0      
 
  EA2161-PANC, Adv Rapalog Resistant PNETs, MLN0128 1 E Total Registrations   1 1 0 0 0 0 09/06/2018 43 11
            1 1 0 0 0 0      
 
  EA2165-Anal, Stg II-III, Nivolumab after CMT 1 E Total Registrations   6 6 5 4 2 0 10/09/2018 90 45
            6 6 5 4 2 0      
 
    2 E Total Registrations   4 4 4 3 2 0 10/09/2018    
            4 4 4 3 2 0      
 
  NRGGI004-Colorectal, Stg IV, dMMR Immuno-Therapy 1 E Total Registrations   7 6 3 2 2 0 04/18/2018 276 118
            7 6 3 2 2 0